Compulsory License Costs Novartis 5 Percent In Thailand Sales
This article was originally published in PharmAsia News
Switzerland's Novartis says Thailand's compulsory-licensing system for key drugs will hold its sales growth in the country to only 15 percent, below the 20 percent it had anticipated. The government overrode the Novartis patent earlier this year, allowing an India-made generic version of its cancer drug Femara (letrozole). Novartis avoided a similar CL on its other cancer drug, Gleevec (imatinib), by agreeing to provide some other drugs for free in Thailand. Novartis has a 4.4 percent sales share in Thailand, third behind Pfizer and Sanofi-Aventis. (Click here for more
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.